Precision Medicine

Researchers have developed a nanoparticle that mimics diseased cells, allowing for rapid screening of cancer targets. It's a key step toward truly personal vaccines.

Promising Phase 2 data for AP-101 shows it slows ALS progression by targeting a key toxic protein, offering new hope beyond purely genetic approaches.

The $2B market for chronic hives is exploding, with new drugs from Sanofi, Celldex, and Novartis creating a seismic shift for patients and investors.

Bionano Genomics brings back OGM pioneer Dr. Alex Hastie as CSO. It's a strategic move to accelerate clinical adoption and restore investor confidence.

A new RNA therapy for obesity is advancing in trials. It promises to reduce harmful visceral fat, preserve muscle, and may only require a twice-yearly dose.

A strategic partnership between IMU Biosciences and Waters Corp. aims to pair AI with advanced hardware, creating a high-definition map of our immune system.

Following a $30M funding round, Mammogen appoints Dr. Elise Berman as CMO to spearhead its genTRU-breast™ test, aiming to solve the dense breast dilemma.

An alliance of biopharma innovators is set to discuss a critical hurdle in medicine: delivering RNA therapies to tissues beyond the liver, a key to unlocking new treatments.

Early trial data for Verastem Oncology's VS-7375 reveals significant anti-tumor activity and a good safety profile, igniting hope for tough-to-treat cancers.

A new law makes Illinois a pioneer, mandating Medicaid coverage for predictive blood tests. Can this tech-driven policy shift the tide on maternal health?

A new startup promises to revolutionize mental health with AI and wearables. But is our biology ready to be read, and are we ready for what it will say?

A new generation of ultra-precise syringes is quietly enabling the future of gene therapy and neuroscience. Here’s why this small innovation is a giant leap.

Decades-old treatments for bladder cancer are failing. Now, a wave of gene and viral therapies is sparking a market revolution and offering new hope.

Illumina's appointment of Eli Lilly's R&D chief isn't just a new hire; it's a strategic masterstroke signaling a deeper push into drug development.

Headwater Science's appointment of Susan Barnes isn't just a new hire; it's a strategic move to build the operational engine for regulatory-grade AI.

A pivotal NCCN guideline update for bladder cancer validates Natera's Signatera test, ushering in a new era of personalized, MRD-guided cancer treatment.

Spotlight Medical's myStage Dx secures tough IVDR CE mark, using AI on standard lab slides to help doctors pinpoint which patients can safely avoid chemo.

Elevar Therapeutics' new trial for lirafugratinib aims for a tumor-agnostic label, a strategic move to redefine cancer treatment beyond a single indication.

A $100k grant will help hospitals decide between local and send-out DNA testing for transplant monitoring, a move that could reshape patient care and markets.

How one family’s harrowing cancer journey sparked a record donation to MCW, aiming to fuel breakthrough research and bridge critical healthcare gaps in Wisconsin.